Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ASNDNASDAQ:CORTNYSE:MYOVNASDAQ:ROIV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeASNDAscendis Pharma A/S$161.52+4.6%$156.29$111.09▼$183.00$9.85B0.41500,815 shs495,599 shsCORTCorcept Therapeutics$70.59-2.1%$67.52$26.87▼$117.33$7.49B0.221.12 million shs1.05 million shsMYOVMyovant Sciences$26.98$26.96$7.67▼$27.06$2.62B2.171.17 million shs2.26 million shsROIVRoivant Sciences$10.76-2.1%$10.49$8.73▼$13.06$7.68B1.235.57 million shs4.60 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceASNDAscendis Pharma A/S+2.10%-9.55%+2.28%+29.22%+15.71%CORTCorcept Therapeutics+2.72%-2.43%+5.13%+5.92%+166.79%MYOVMyovant Sciences0.00%0.00%0.00%0.00%0.00%ROIVRoivant Sciences+3.19%-5.01%+11.46%+4.77%-1.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationASNDAscendis Pharma A/S3.382 of 5 stars4.53.00.00.02.71.70.6CORTCorcept Therapeutics4.5144 of 5 stars3.51.00.04.22.14.21.9MYOVMyovant SciencesN/AN/AN/AN/AN/AN/AN/AN/AROIVRoivant Sciences2.3198 of 5 stars3.51.00.00.04.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceASNDAscendis Pharma A/S 3.00Buy$216.0733.77% UpsideCORTCorcept Therapeutics 3.00Buy$138.2595.85% UpsideMYOVMyovant Sciences 0.00N/AN/AN/AROIVRoivant Sciences 3.00Buy$17.5062.64% UpsideCurrent Analyst Ratings BreakdownLatest MYOV, ASND, ROIV, and CORT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/12/2025ASNDAscendis Pharma A/SCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$200.00 ➝ $200.005/6/2025CORTCorcept TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$135.005/6/2025CORTCorcept TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$150.00 ➝ $145.005/5/2025ASNDAscendis Pharma A/SMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$180.00 ➝ $250.005/2/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$205.00 ➝ $210.005/2/2025ASNDAscendis Pharma A/SJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $245.005/2/2025ASNDAscendis Pharma A/SWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $212.005/2/2025ASNDAscendis Pharma A/SEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$260.00 ➝ $280.004/21/2025ROIVRoivant SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.004/16/2025ASNDAscendis Pharma A/SRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$205.004/3/2025CORTCorcept TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$128.00 ➝ $131.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookASNDAscendis Pharma A/S$368.70M26.71N/AN/A($1.88) per share-85.91CORTCorcept Therapeutics$685.45M10.92$1.04 per share67.96$4.92 per share14.35MYOVMyovant Sciences$230.97M11.36N/AN/A($5.04) per share-5.35ROIVRoivant Sciences$122.59M62.63N/AN/A$7.76 per share1.39Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateASNDAscendis Pharma A/S-$409.12M-$6.28N/A673.00N/A-104.54%N/A-39.23%N/ACORTCorcept Therapeutics$106.14M$1.1656.0238.16N/A22.35%24.54%20.24%N/AMYOVMyovant Sciences-$205.98M-$1.91N/AN/AN/A-48.47%N/A-39.36%N/AROIVRoivant Sciences$4.35B-$0.15N/AN/AN/A-119.54%-14.05%-12.81%5/29/2025 (Estimated)Latest MYOV, ASND, ROIV, and CORT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025ROIVRoivant Sciences-$0.16N/AN/AN/A$62.17 millionN/A5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 million5/1/2025Q1 2025ASNDAscendis Pharma A/S-$1.56-$1.66-$0.10-$1.66$98.56 million$123.97 million2/26/2025Q4 2024CORTCorcept Therapeutics$0.37$0.26-$0.11$0.26$200.12 million$181.89 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthASNDAscendis Pharma A/SN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AMYOVMyovant SciencesN/AN/AN/AN/AN/AROIVRoivant SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioASNDAscendis Pharma A/SN/A1.170.84CORTCorcept Therapeutics0.013.703.64MYOVMyovant SciencesN/A1.571.45ROIVRoivant SciencesN/A37.9137.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipASNDAscendis Pharma A/SN/ACORTCorcept Therapeutics93.61%MYOVMyovant Sciences30.62%ROIVRoivant Sciences64.76%Insider OwnershipCompanyInsider OwnershipASNDAscendis Pharma A/S40.00%CORTCorcept Therapeutics20.80%MYOVMyovant Sciences1.90%ROIVRoivant Sciences7.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableASNDAscendis Pharma A/S64060.97 million36.41 millionOptionableCORTCorcept Therapeutics300106.05 million83.30 millionOptionableMYOVMyovant Sciences40797.24 million95.39 millionNot OptionableROIVRoivant Sciences860713.55 million657.18 millionOptionableMYOV, ASND, ROIV, and CORT HeadlinesRecent News About These CompaniesWho is Vivek Ramaswamy? Ohio Republican Party endorses entrepreneur for governor in 2026May 12 at 5:04 PM | mansfieldnewsjournal.comSchonfeld Strategic Advisors LLC Reduces Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)May 11 at 4:41 AM | marketbeat.comNorthern Trust Corp Boosts Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)May 11 at 4:33 AM | marketbeat.comVivek Ramaswamy Sells 273,959 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) StockMay 11 at 4:14 AM | marketbeat.comDME Capital Management LP Sells 36,973 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)May 10 at 7:19 AM | marketbeat.comSelon un récent dépôt auprès de la SEC, un initié de Roivant Sciences a vendu des actions pour une valeur de 10 129 810 dollars.May 9, 2025 | zonebourse.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Purchased by Caption Management LLCMay 9, 2025 | marketbeat.comEnvestnet Asset Management Inc. Makes New Investment in Roivant Sciences Ltd. (NASDAQ:ROIV)May 9, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 25,367 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)May 8, 2025 | marketbeat.com24,000 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Bellevue Group AGMay 7, 2025 | marketbeat.com84,091 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Purchased by Raymond James Financial Inc.May 7, 2025 | marketbeat.comBaker BROS. Advisors LP Buys 969,057 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)May 6, 2025 | marketbeat.comRoivant Sciences (NASDAQ:ROIV) Hits New 52-Week High - Time to Buy?May 3, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside PotentialMay 2, 2025 | insidermonkey.comRoivant Sciences Ltd. (ROIV): Among David Einhorn’s Stock Picks with Huge Upside PotentialMay 2, 2025 | msn.comRoivant Sciences Ltd. (NASDAQ:ROIV) Shares Acquired by PDT Partners LLCMay 1, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Position Boosted by TOMS Capital Investment Management LPMay 1, 2025 | marketbeat.comRoivant Sciences Ltd. (ROIV): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside PotentialApril 29, 2025 | insidermonkey.comIntegrated Wealth Concepts LLC Purchases 41,564 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)April 29, 2025 | marketbeat.comRoivant Sciences Ltd. (NASDAQ:ROIV) Position Increased by Tower Research Capital LLC TRCApril 29, 2025 | marketbeat.comGilder Gagnon Howe & Co. LLC Acquires Shares of 1,162,986 Roivant Sciences Ltd. (NASDAQ:ROIV)April 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYOV, ASND, ROIV, and CORT Company DescriptionsAscendis Pharma A/S NASDAQ:ASND$161.52 +7.09 (+4.59%) As of 04:00 PM EasternAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Corcept Therapeutics NASDAQ:CORT$70.59 -1.55 (-2.15%) As of 04:00 PM EasternCorcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Myovant Sciences NYSE:MYOVMyovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.Roivant Sciences NASDAQ:ROIV$10.76 -0.23 (-2.09%) As of 04:00 PM EasternRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Stock Surges on Bullish News: How High Could It Climb? NuScale Power in Rebound Mode With Short-Squeeze a Possibility Why Amazon May Never Dip Below $200 Again eBay Nears Big Breakout: Time to Buy the Under-the-Radar Winner? Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long Why Boeing May Be Ready to Take Off After Latest Developments Goldman Sachs Warns of 20% Market Sell-Off: Are They Right? 3 Huge S&P 500 Winners From Trump Trade Deal & The Biggest Loser Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
